ADC Therapeutics America, Inc.

ADC Therapeutics America, Inc. is a foreign-owned, for-profit corporate entity registered in the System for Award Management (SAM.gov) that provides specialized pharmaceutical and biotechnology services to federal agencies. The company focuses on pharmaceutical research, development, and support services, with a particular emphasis on drug testing, stability services, and pharmaceutical product maintenance. While specific details about the company's broader corporate structure are not provided in the award documentation, the federal contract history suggests the organization specializes in advanced pharmaceutical research and support services for complex medical products.

The company has secured federal contract awards primarily in the pharmaceutical and hematological product domains, with notable work for agencies like the National Cancer Institute and the Department of Veterans Affairs. Its most recent significant contract is a $194,000 firm fixed-price purchase order from the National Cancer Institute for stability testing services and drug master file maintenance for an antibody drug conjugate (ADCT-701), with a completion date of December 29, 2027. The contract involves technical scientific services related to pharmaceutical research and does not utilize any specific set-aside designations. This award demonstrates the company's capability to provide specialized, high-value scientific services to federal research and healthcare agencies.

ADC Therapeutics America, Inc. holds multiple Federal Supply Schedule (FSS) contracts, specifically in the Pharmaceuticals and Drugs (FSS-61-IB) GSA Schedule category. The primary FSS contract with the Department of Veterans Affairs, valued at $540,000, runs from October 1, 2021, through September 30, 2026, and is a multiple-award contract covering drugs, pharmaceuticals, and hematology-related products. This contract allows the VA to place task orders for various pharmaceutical goods across the 65 I B Federal Supply Classification. An additional interim agreement under the same FSS schedule was also awarded, valued at $25,000, further solidifying the company's presence in federal pharmaceutical procurement vehicles. These contracts position ADC Therapeutics America, Inc. as a potential supplier of pharmaceutical products and related services to federal healthcare institutions.